Genzyme Corporation

The Brigham and Women's Hospital, Inc.

Robert J Miller

Clark Qun Pan

Luis Z Avila

James E Stefano

Qun Zhou

Lauren Young

Pradeep K Dhal

Pericles Calias

Yunxiang Zhu

Michael Reardon

Patrick Finn

Paul A Konowicz

Andreas Peer

Duncan E Paterson

John Harrahy

Joseph P Kutzko

Xiaoyang Zheng

James W Burns

Diego A Gianolio

Huawei Qiu

Rajesh Vasant Kamath

Bo Chen

Xuejian Xu

Kanwen Yang

Stephen Randall Holmes-Farley

C Michael Philbrook

James R Olson

Arthur O Tzianabos

Andrew B Onderdonk

Alan E Walts

Sharon R Nahill

Peter D McDonnell

Mark M Staveski

Steven C Polomoscanik

S Randall Holmes-Farley

Philip Just Larsen

Thomas Huebschle

Erika E Johnston

Thorsten Schmidt

Ian Davison

Kevin C Skinner

Aviva Shiedlin

Chinyere Agbugba

Michael R Reardon

Stephen Randall Holms-Farley

Duncan E Patterson

Duncan Patterson

Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.

Oligosaccharide-protein conjugates

Polydiallylamine copolymers are copolymers comprising monomers of polydiallylamine and either polyvinlyamine or polyallylamine. Polydiallylamine copolymers are often crosslinked. The polydiallyamine copolymers are useful as pharmaceutical compositions and may be used in the treatment of type 2 diabetes and for mitigating the complications of type 2 diabetes.

Crosslinked polydiallymine copolymers for the treatment of type 2 diabetes

The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.

Site-specific antibody-drug conjugation through glycoengineering

Amine functional polyamides comprise amine and ammonium groups along the polymer chain. Amine functional polyamides can be used as pharmaceutical agents and in pharmaceutical compositions. The amine functional polyamides are particularly useful in the treatment or prevention of mucositis and infection, specifically oral mucositis, surgical site infection, and lung infection associated with cystic fibrosis.

Amine functional polyamides

Dendrimers comprising N-acyl urea terminal moieties are described herein. The dendrimers can be used, for example, in the treatment of arthritis.

Chemically modified dendrimers

The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.

The invention relates to immunomodulatory compositions and related methods. The immunomodulatory compositions of a formula disclosed herein are useful for the prevention of sepsis and the treatment and prevention of diseases associated with inflammation and/or NOS.

Immunodulatory compositions and methods of use thereof

Growing community of inventors

E. Bridgewater, MA, United States of America

Robert J Miller